{"protocolSection": {"identificationModule": {"nctId": "NCT00467740", "orgStudyIdInfo": {"id": "1222.6"}, "secondaryIdInfos": [{"id": "EUDRACT 2006-004829-29"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma", "officialTitle": "Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (4 Doses) Delivered by the Respimat\u00ae Inhaler in Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2014-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-05"}, "primaryCompletionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-04-30", "studyFirstSubmitQcDate": "2007-04-30", "studyFirstPostDateStruct": {"date": "2007-05-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-03-28", "resultsFirstSubmitQcDate": "2014-06-10", "resultsFirstPostDateStruct": {"date": "2014-06-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-06-17", "lastUpdatePostDateStruct": {"date": "2014-06-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Boehringer Ingelheim, Study Chair", "oldOrganization": "Boehringer Ingelheim"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat\u00ae inhaler for four weeks in patients with asthma. The selection of the optimum dose(s) will be based on bronchodilator efficacy (how well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount of the medication found in your blood)."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT"}, "enrollmentInfo": {"count": 296, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "BI 1744 CL"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough FEV1 Response After 4 Weeks", "description": "Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "timeFrame": "Baseline and 4 weeks"}], "secondaryOutcomes": [{"measure": "Weekly Mean Pre-dose Morning PEFR After 4 Weeks", "description": "Response was defined as change from baseline. Baseline peak expiratory flow response (PEFR) was defined as the mean of the morning PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Trough FEV1 Response After 1 Week", "description": "Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "timeFrame": "Baseline and 1 week"}, {"measure": "Trough FEV1 Response After 2 Weeks", "description": "Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Trough FVC Response After 1 Week", "description": "Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "timeFrame": "Baseline and 1 week"}, {"measure": "Trough FVC Response After 2 Weeks", "description": "Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Trough FVC Response After 4 Weeks", "description": "Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4"}, {"measure": "Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. FVC AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Day 1"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 1"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 2"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 4"}, {"measure": "Peak FEV1 (0-3h) Response At Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose at day 1"}, {"measure": "Peak FEV1 (0-3h) Response After 1 Week", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 week"}, {"measure": "Peak FEV1 (0-3h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks"}, {"measure": "Peak FEV1 (0-3h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks"}, {"measure": "Peak FVC (0-3h) Response At Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks"}, {"measure": "Peak FVC (0-3h) Response After 1 Week", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks"}, {"measure": "Peak FVC (0-3h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks"}, {"measure": "Peak FVC (0-3h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks"}, {"measure": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 6-12 h (AUC 6-12h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.", "timeFrame": "1 hour (h) prior to dose on first day of randomized treatment (baseline) and 1h, 3h, 6h, 9h, 12h relative to dose at Week 4"}, {"measure": "Weekly Mean Evening PEFR After 4 Weeks", "description": "Response was defined as change from baseline. Baseline PEFR was defined as the mean of the evening PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "timeFrame": "Baseline and 4 weeks"}, {"measure": "PEFR Variability After 4 Weeks", "description": "PEFR variability represents the absolute difference between the highest morning PEFR value and the highest evening PEFR value of 1 day, divided by the arithmetic mean of these 2 PEFR values and expressed as a percent, weekly means.", "timeFrame": "4 weeks"}, {"measure": "Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks", "description": "Weekly mean number of occasions of rescue therapy used per day (prn salbutamol \\[albuterol\\]) as assessed by the e-Diary (e-Diary incorporated in AM2+).", "timeFrame": "4 weeks"}, {"measure": "Area Under Curve From 0 to 3 Hours (AUC0-3)", "description": "AUC0-3 represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration"}, {"measure": "Maximum Concentration (Cmax)", "description": "Cmax represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration"}, {"measure": "Time From Dosing to the Maximum Concentration (Tmax)", "description": "tmax represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration"}, {"measure": "Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)", "description": "AUC0-3,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3 at steady state.", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration"}, {"measure": "Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)", "description": "AUC0-6,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=6 at steady state.", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration"}, {"measure": "Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)", "description": "AUC0-24,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=24 at steady state.", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration"}, {"measure": "Maximum Concentration at Steady State (Cmax,ss)", "description": "Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration"}, {"measure": "Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)", "description": "tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration"}, {"measure": "Total Score in Asthma Control Questionnaire After 4 Weeks", "description": "Adequacy of asthma control was assessed using a scale of: 0=totally controlled, to 6=Severely uncontrolled.", "timeFrame": "4 weeks"}, {"measure": "Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination", "description": "Clinical relevant abnormalities for vital signs, ECG and physical examination. Any new or clinically relevant worsening of baseline conditions was reported as adverse events.", "timeFrame": "4 weeks"}, {"measure": "Laboratory Testing: Average Change From Baseline of Potassium", "description": "Laboratory testing: Average change from baseline of potassium measured on test-days. Pre-dose value on test day 1 is the baseline value.", "timeFrame": "Baseline and 29 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions\n2. Male or female patients, 18 years of age or older\n3. Diagnosis of asthma (GINA)\n4. Pre-bronchodilator FEV1 greater than or equal to 60% predicted and \\<90% predicted (ECSC);\n5. Increase in FEV1 greater than or equal to 12% and 200 ml 15 minutes after 400\u00b5g salbutamol (albuterol) at Visit 1\n6. Patient must have been taking Inhaled Corticosteroids for at least 12 weeks prior to screening, and must have been receiving a stable low/moderate dose for at least 6 weeks prior to screening.\n7. Patients must be able to perform technically acceptable pulmonary function tests and PEF measurements, and must be able to maintain records (Patient Daily e-Diary) during the study period as required in the protocol\n8. Patients must be able to inhale medication in a competent manner from the Respimat\u00ae inhaler and from a metered dose inhaler (MDI).\n\nExclusion Criteria:\n\n1. Patients with a smoking history of more than 10 pack years\n2. Patients with any of the following conditions: a diagnosis of thyrotoxicosis, a diagnosis of paroxysmal tachycardia (\\>100 beats per minute), a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \\>450 ms), a history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)\n3. Patients with any of the following conditions: a history of myocardial infarction within 1 year of screening visit (Visit 1), a diagnosis of clinically relevant cardiac arrhythmia, a history of cor pulmonale, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed), a history of life-threatening pulmonary obstruction, a history of cystic fibrosis, clinically evident bronchiectasis, a history of significant alcohol or drug abuse\n4. Patients who have undergone thoracotomy with pulmonary resection\n5. Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)\n6. Pregnant or nursing women\n7. Women of childbearing potential not using a highly effective method of birth control. Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at least 2 years\n8. Patients who have previously been randomized in this study or are currently participating in another study\n9. Patients who are unable to comply with pulmonary medication restrictions prior to randomization", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1222.6.064 Arthur F. Gelb Medical Corporation, Lakewood", "city": "Lakewood", "state": "California", "country": "United States", "geoPoint": {"lat": 33.85363, "lon": -118.13396}}, {"facility": "1222.6.062 Boehringer Ingelheim Investigational Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "1222.6.066 Allergy & Asthma Medical Group and Rsrch Ctr, APC", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "1222.6.069 Allergy Associates Medical Group", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "1222.6.068 National Jewish Medical Center", "city": "Denver", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "1222.6.073 Boehringer Ingelheim Investigational Site", "city": "Wheat Ridge", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "1222.6.067 Northeast Medical Research Associates, Inc", "city": "North Darthmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "1222.6.061 Center for Human Genomics", "city": "Winston-Salem", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "1222.6.072 Boehringer Ingelheim Investigational Site", "city": "Kileen", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "1222.6.071 Pulmonary Consultants", "city": "Tacoma", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "1222.6.017 Boehringer Ingelheim Investigational Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "1222.6.006 Boehringer Ingelheim Investigational Site", "city": "Vancouver", "state": "British Columbia", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "1222.6.012 Boehringer Ingelheim Investigational Site", "city": "Winnipeg", "state": "Manitoba", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "1222.6.016 Boehringer Ingelheim Investigational Site", "city": "Winnipeg", "state": "Manitoba", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "1222.6.011 Boehringer Ingelheim Investigational Site", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "1222.6.003 Boehringer Ingelheim Investigational Site", "city": "Mississauga", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "1222.6.013 Boehringer Ingelheim Investigational Site", "city": "Ottawa", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "1222.6.005 Boehringer Ingelheim Investigational Site", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "1222.6.009 Boehringer Ingelheim Investigational Site", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "1222.6.008 Boehringer Ingelheim Investigational Site", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "1222.6.015 Boehringer Ingelheim Investigational Site", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "1222.6.007 Boehringer Ingelheim Investigational Site", "city": "Sherbrooke", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "1222.6.002 Boehringer Ingelheim Investigational Site", "city": "Ste-Foy", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.75615, "lon": -71.29543}}, {"facility": "1222.6.004 Boehringer Ingelheim Investigational Site", "city": "Saskatoon", "state": "Saskatchewan", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "1222.6.3303A Boehringer Ingelheim Investigational Site", "city": "Bethune Cedex", "country": "France", "geoPoint": {"lat": 50.53333, "lon": 2.63333}}, {"facility": "1222.6.3308A Boehringer Ingelheim Investigational Site", "city": "Briancon", "country": "France", "geoPoint": {"lat": 44.89978, "lon": 6.64201}}, {"facility": "1222.6.3302A Boehringer Ingelheim Investigational Site", "city": "Grenoble", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "1222.6.3306A Boehringer Ingelheim Investigational Site", "city": "Lille", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "1222.6.3301A Boehringer Ingelheim Investigational Site", "city": "Montpellier", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "1222.6.3304A Boehringer Ingelheim Investigational Site", "city": "N\u00eemes", "country": "France", "geoPoint": {"lat": 43.83333, "lon": 4.35}}, {"facility": "1222.6.3305A Boehringer Ingelheim Investigational Site", "city": "Saint-Pierre Cedex - La R\u00e9union", "country": "France"}, {"facility": "1222.6.031 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1222.6.034 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "1222.6.037 Boehringer Ingelheim Investigational Site", "city": "Gauting", "country": "Germany", "geoPoint": {"lat": 48.06919, "lon": 11.37703}}, {"facility": "1222.6.038 Boehringer Ingelheim Investigational Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "1222.6.032 Boehringer Ingelheim Investigational Site", "city": "R\u00fcdersdorf", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "1222.6.036 Boehringer Ingelheim Investigational Site", "city": "Wiesloch", "country": "Germany", "geoPoint": {"lat": 49.29504, "lon": 8.69846}}]}, "referencesModule": {"references": [{"pmid": "26283085", "type": "DERIVED", "citation": "O'Byrne PM, D'Urzo T, Beck E, Flezar M, Gahlemann M, Hart L, Blahova Z, Toorawa R, Beeh KM. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting beta2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. Respir Res. 2015 Aug 18;16(1):97. doi: 10.1186/s12931-015-0249-8."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "FG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "FG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "FG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "FG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "54"}, {"groupId": "FG001", "numSubjects": "61"}, {"groupId": "FG002", "numSubjects": "60"}, {"groupId": "FG003", "numSubjects": "60"}, {"groupId": "FG004", "numSubjects": "61"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}, {"groupId": "FG001", "numSubjects": "58"}, {"groupId": "FG002", "numSubjects": "58"}, {"groupId": "FG003", "numSubjects": "59"}, {"groupId": "FG004", "numSubjects": "61"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "BG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "60"}, {"groupId": "BG003", "value": "60"}, {"groupId": "BG004", "value": "61"}, {"groupId": "BG005", "value": "296"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.59", "spread": "14.11"}, {"groupId": "BG001", "value": "45.36", "spread": "15.12"}, {"groupId": "BG002", "value": "46.17", "spread": "12.96"}, {"groupId": "BG003", "value": "46.25", "spread": "14.45"}, {"groupId": "BG004", "value": "44.62", "spread": "12.95"}, {"groupId": "BG005", "value": "45.23", "spread": "13.88"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "30"}, {"groupId": "BG003", "value": "34"}, {"groupId": "BG004", "value": "33"}, {"groupId": "BG005", "value": "170"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "30"}, {"groupId": "BG003", "value": "26"}, {"groupId": "BG004", "value": "28"}, {"groupId": "BG005", "value": "126"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough FEV1 Response After 4 Weeks", "description": "Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.004", "spread": "0.034"}, {"groupId": "OG001", "value": "0.083", "spread": "0.032"}, {"groupId": "OG002", "value": "0.090", "spread": "0.032"}, {"groupId": "OG003", "value": "0.080", "spread": "0.032"}, {"groupId": "OG004", "value": "0.150", "spread": "0.032"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0754", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.080", "ciPctValue": "95", "ciLowerLimit": "-0.008", "ciUpperLimit": "0.167", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.045", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0571", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Median Difference (Final Values)", "paramValue": "0.086", "ciPctValue": "95", "ciLowerLimit": "-0.003", "ciUpperLimit": "0.174", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.045", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0906", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.076", "ciPctValue": "95", "ciLowerLimit": "-0.012", "ciUpperLimit": "0.164", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.045", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.147", "ciPctValue": "95", "ciLowerLimit": "0.059", "ciUpperLimit": "0.234", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Mean Pre-dose Morning PEFR After 4 Weeks", "description": "Response was defined as change from baseline. Baseline peak expiratory flow response (PEFR) was defined as the mean of the morning PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/minute", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "368.18", "spread": "5.713"}, {"groupId": "OG001", "value": "384.42", "spread": "5.377"}, {"groupId": "OG002", "value": "396.06", "spread": "5.419"}, {"groupId": "OG003", "value": "404.26", "spread": "5.465"}, {"groupId": "OG004", "value": "411.13", "spread": "5.377"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0393", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "16.238", "ciPctValue": "95", "ciLowerLimit": "0.801", "ciUpperLimit": "31.675", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.843", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "27.878", "ciPctValue": "95", "ciLowerLimit": "12.379", "ciUpperLimit": "43.378", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.875", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "36.072", "ciPctValue": "95", "ciLowerLimit": "20.512", "ciUpperLimit": "51.633", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.906", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "42.943", "ciPctValue": "95", "ciLowerLimit": "27.498", "ciUpperLimit": "58.389", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.848", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Response After 1 Week", "description": "Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 1 week", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.007", "spread": "0.033"}, {"groupId": "OG001", "value": "0.060", "spread": "0.031"}, {"groupId": "OG002", "value": "0.094", "spread": "0.032"}, {"groupId": "OG003", "value": "0.106", "spread": "0.031"}, {"groupId": "OG004", "value": "0.166", "spread": "0.031"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1264", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.067", "ciPctValue": "95", "ciLowerLimit": "-0.019", "ciUpperLimit": "0.154", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0232", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.101", "ciPctValue": "95", "ciLowerLimit": "0.014", "ciUpperLimit": "0.188", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0106", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.114", "ciPctValue": "95", "ciLowerLimit": "0.027", "ciUpperLimit": "0.200", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.173", "ciPctValue": "95", "ciLowerLimit": "0.087", "ciUpperLimit": "0.260", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.044", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Response After 2 Weeks", "description": "Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.009", "spread": "0.036"}, {"groupId": "OG001", "value": "0.094", "spread": "0.034"}, {"groupId": "OG002", "value": "0.080", "spread": "0.034"}, {"groupId": "OG003", "value": "0.034", "spread": "0.034"}, {"groupId": "OG004", "value": "0.131", "spread": "0.034"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0329", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.103", "ciPctValue": "95", "ciLowerLimit": "0.008", "ciUpperLimit": "0.198", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0666", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.089", "ciPctValue": "95", "ciLowerLimit": "-0.006", "ciUpperLimit": "0.184", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3738", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.043", "ciPctValue": "95", "ciLowerLimit": "-0.052", "ciUpperLimit": "0.137", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0037", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.140", "ciPctValue": "95", "ciLowerLimit": "0.046", "ciUpperLimit": "0.234", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Response After 1 Week", "description": "Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 1 week", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.001", "spread": "0.036"}, {"groupId": "OG001", "value": "0.053", "spread": "0.034"}, {"groupId": "OG002", "value": "0.044", "spread": "0.034"}, {"groupId": "OG003", "value": "0.070", "spread": "0.034"}, {"groupId": "OG004", "value": "0.131", "spread": "0.034"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2646", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.051", "ciPctValue": "95", "ciLowerLimit": "-0.039", "ciUpperLimit": "0.142", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.046", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3527", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Median Difference (Final Values)", "paramValue": "0.043", "ciPctValue": "95", "ciLowerLimit": "-0.048", "ciUpperLimit": "0.135", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.046", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1369", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.069", "ciPctValue": "95", "ciLowerLimit": "-0.022", "ciUpperLimit": "0.160", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.046", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0051", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.130", "ciPctValue": "95", "ciLowerLimit": "0.039", "ciUpperLimit": "0.221", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.046", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Response After 2 Weeks", "description": "Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.029", "spread": "0.041"}, {"groupId": "OG001", "value": "0.098", "spread": "0.039"}, {"groupId": "OG002", "value": "0.069", "spread": "0.039"}, {"groupId": "OG003", "value": "-0.002", "spread": "0.038"}, {"groupId": "OG004", "value": "0.100", "spread": "0.038"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0170", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.127", "ciPctValue": "95", "ciLowerLimit": "0.023", "ciUpperLimit": "0.232", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0646", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.099", "ciPctValue": "95", "ciLowerLimit": "-0.006", "ciUpperLimit": "0.204", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6020", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.028", "ciPctValue": "95", "ciLowerLimit": "-0.077", "ciUpperLimit": "0.132", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0147", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.130", "ciPctValue": "95", "ciLowerLimit": "0.026", "ciUpperLimit": "0.233", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Trough FVC Response After 4 Weeks", "description": "Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVC performed at -10 mins prior to study drug inhalation at the end of the dosing interval.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "59"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.018", "spread": "0.041"}, {"groupId": "OG001", "value": "0.055", "spread": "0.039"}, {"groupId": "OG002", "value": "0.076", "spread": "0.039"}, {"groupId": "OG003", "value": "0.042", "spread": "0.039"}, {"groupId": "OG004", "value": "0.166", "spread": "0.038"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4902", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.037", "ciPctValue": "95", "ciLowerLimit": "-0.068", "ciUpperLimit": "0.142", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2832", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.058", "ciPctValue": "95", "ciLowerLimit": "-0.048", "ciUpperLimit": "0.164", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.054", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6516", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.024", "ciPctValue": "95", "ciLowerLimit": "-0.081", "ciUpperLimit": "0.130", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.054", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0060", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.147", "ciPctValue": "95", "ciLowerLimit": "0.042", "ciUpperLimit": "0.252", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.053", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.091", "spread": "0.037"}, {"groupId": "OG001", "value": "0.269", "spread": "0.035"}, {"groupId": "OG002", "value": "0.229", "spread": "0.035"}, {"groupId": "OG003", "value": "0.190", "spread": "0.035"}, {"groupId": "OG004", "value": "0.323", "spread": "0.035"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.178", "ciPctValue": "95", "ciLowerLimit": "0.079", "ciUpperLimit": "0.277", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0070", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.137", "ciPctValue": "95", "ciLowerLimit": "0.038", "ciUpperLimit": "0.237", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0512", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.099", "ciPctValue": "95", "ciLowerLimit": "-0.001", "ciUpperLimit": "0.198", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.232", "ciPctValue": "95", "ciLowerLimit": "0.133", "ciUpperLimit": "0.331", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Vital Capacity (FVC) Area Under Curve 0-6 h (AUC 0-6h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. FVC AUC 0-6h was calculated from 0-6 hours post-dose using the trapezoidal rule, divided by the observation time (6h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h, 4h, 5h, 6h relative to dose at Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.076", "spread": "0.045"}, {"groupId": "OG001", "value": "0.159", "spread": "0.042"}, {"groupId": "OG002", "value": "0.154", "spread": "0.043"}, {"groupId": "OG003", "value": "0.113", "spread": "0.043"}, {"groupId": "OG004", "value": "0.267", "spread": "0.042"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1811", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.082", "ciPctValue": "95", "ciLowerLimit": "-0.039", "ciUpperLimit": "0.203", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.061", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2118", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.077", "ciPctValue": "95", "ciLowerLimit": "-0.044", "ciUpperLimit": "0.199", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.062", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5504", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.037", "ciPctValue": "95", "ciLowerLimit": "-0.085", "ciUpperLimit": "0.158", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.062", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0022", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.191", "ciPctValue": "95", "ciLowerLimit": "0.069", "ciUpperLimit": "0.312", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.062", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Day 1", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.092", "spread": "0.030"}, {"groupId": "OG001", "value": "0.271", "spread": "0.028"}, {"groupId": "OG002", "value": "0.275", "spread": "0.028"}, {"groupId": "OG003", "value": "0.265", "spread": "0.028"}, {"groupId": "OG004", "value": "0.383", "spread": "0.028"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.178", "ciPctValue": "95", "ciLowerLimit": "0.102", "ciUpperLimit": "0.255", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.183", "ciPctValue": "95", "ciLowerLimit": "0.106", "ciUpperLimit": "0.260", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.173", "ciPctValue": "95", "ciLowerLimit": "0.096", "ciUpperLimit": "0.250", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.291", "ciPctValue": "95", "ciLowerLimit": "0.214", "ciUpperLimit": "0.367", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.039", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 1", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.062", "spread": "0.034"}, {"groupId": "OG001", "value": "0.252", "spread": "0.032"}, {"groupId": "OG002", "value": "0.258", "spread": "0.033"}, {"groupId": "OG003", "value": "0.219", "spread": "0.032"}, {"groupId": "OG004", "value": "0.325", "spread": "0.032"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.190", "ciPctValue": "95", "ciLowerLimit": "0.101", "ciUpperLimit": "0.279", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.045", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.196", "ciPctValue": "95", "ciLowerLimit": "0.107", "ciUpperLimit": "0.286", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.046", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0007", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.157", "ciPctValue": "95", "ciLowerLimit": "0.067", "ciUpperLimit": "0.246", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.045", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.263", "ciPctValue": "95", "ciLowerLimit": "0.174", "ciUpperLimit": "0.352", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.045", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 2", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 2", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.084", "spread": "0.038"}, {"groupId": "OG001", "value": "0.298", "spread": "0.036"}, {"groupId": "OG002", "value": "0.240", "spread": "0.036"}, {"groupId": "OG003", "value": "0.172", "spread": "0.036"}, {"groupId": "OG004", "value": "0.311", "spread": "0.035"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.214", "ciPctValue": "95", "ciLowerLimit": "0.115", "ciUpperLimit": "0.313", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0021", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.156", "ciPctValue": "95", "ciLowerLimit": "0.057", "ciUpperLimit": "0.255", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0795", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.088", "ciPctValue": "95", "ciLowerLimit": "-0.010", "ciUpperLimit": "0.187", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.227", "ciPctValue": "95", "ciLowerLimit": "0.129", "ciUpperLimit": "0.326", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.050", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-3 h (AUC 0-3h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and 30 min, 1h, 2h, 3h relative to dose at Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.092", "spread": "0.037"}, {"groupId": "OG001", "value": "0.271", "spread": "0.035"}, {"groupId": "OG002", "value": "0.224", "spread": "0.035"}, {"groupId": "OG003", "value": "0.192", "spread": "0.035"}, {"groupId": "OG004", "value": "0.332", "spread": "0.035"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Median Difference (Final Values)", "paramValue": "0.179", "ciPctValue": "95", "ciLowerLimit": "0.082", "ciUpperLimit": "0.276", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.049", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0077", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.132", "ciPctValue": "95", "ciLowerLimit": "0.035", "ciUpperLimit": "0.229", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.049", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0427", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.100", "ciPctValue": "95", "ciLowerLimit": "0.003", "ciUpperLimit": "0.197", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.049", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.240", "ciPctValue": "95", "ciLowerLimit": "0.143", "ciUpperLimit": "0.336", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.049", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response At Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose at day 1", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.203", "spread": "0.036"}, {"groupId": "OG001", "value": "0.372", "spread": "0.034"}, {"groupId": "OG002", "value": "0.378", "spread": "0.034"}, {"groupId": "OG003", "value": "0.376", "spread": "0.034"}, {"groupId": "OG004", "value": "0.499", "spread": "0.034"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.169", "ciPctValue": "95", "ciLowerLimit": "0.074", "ciUpperLimit": "0.263", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.174", "ciPctValue": "95", "ciLowerLimit": "0.080", "ciUpperLimit": "0.269", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.173", "ciPctValue": "95", "ciLowerLimit": "0.078", "ciUpperLimit": "0.268", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.296", "ciPctValue": "95", "ciLowerLimit": "0.202", "ciUpperLimit": "0.390", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response After 1 Week", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 week", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.170", "spread": "0.036"}, {"groupId": "OG001", "value": "0.343", "spread": "0.034"}, {"groupId": "OG002", "value": "0.355", "spread": "0.034"}, {"groupId": "OG003", "value": "0.308", "spread": "0.034"}, {"groupId": "OG004", "value": "0.407", "spread": "0.034"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.173", "ciPctValue": "95", "ciLowerLimit": "0.078", "ciUpperLimit": "0.268", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.185", "ciPctValue": "95", "ciLowerLimit": "0.090", "ciUpperLimit": "0.281", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0047", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.138", "ciPctValue": "95", "ciLowerLimit": "0.043", "ciUpperLimit": "0.233", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.237", "ciPctValue": "95", "ciLowerLimit": "0.142", "ciUpperLimit": "0.332", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.048", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.182", "spread": "0.041"}, {"groupId": "OG001", "value": "0.386", "spread": "0.039"}, {"groupId": "OG002", "value": "0.335", "spread": "0.039"}, {"groupId": "OG003", "value": "0.261", "spread": "0.038"}, {"groupId": "OG004", "value": "0.403", "spread": "0.038"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.204", "ciPctValue": "95", "ciLowerLimit": "0.096", "ciUpperLimit": "0.312", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.055", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0057", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.153", "ciPctValue": "95", "ciLowerLimit": "0.045", "ciUpperLimit": "0.261", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.055", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1513", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.079", "ciPctValue": "95", "ciLowerLimit": "-0.029", "ciUpperLimit": "0.186", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.055", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.221", "ciPctValue": "95", "ciLowerLimit": "0.114", "ciUpperLimit": "0.328", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.055", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FEV1 (0-3h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.198", "spread": "0.040"}, {"groupId": "OG001", "value": "0.363", "spread": "0.038"}, {"groupId": "OG002", "value": "0.315", "spread": "0.038"}, {"groupId": "OG003", "value": "0.279", "spread": "0.038"}, {"groupId": "OG004", "value": "0.430", "spread": "0.038"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0022", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.166", "ciPctValue": "95", "ciLowerLimit": "0.060", "ciUpperLimit": "0.271", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.054", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0307", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.117", "ciPctValue": "95", "ciLowerLimit": "0.011", "ciUpperLimit": "0.223", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.054", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1320", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.081", "ciPctValue": "95", "ciLowerLimit": "-0.025", "ciUpperLimit": "0.187", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.054", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.232", "ciPctValue": "95", "ciLowerLimit": "0.127", "ciUpperLimit": "0.337", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.054", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FVC (0-3h) Response At Day 1", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.218", "spread": "0.041"}, {"groupId": "OG001", "value": "0.297", "spread": "0.039"}, {"groupId": "OG002", "value": "0.315", "spread": "0.039"}, {"groupId": "OG003", "value": "0.315", "spread": "0.039"}, {"groupId": "OG004", "value": "0.398", "spread": "0.039"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1585", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.079", "ciPctValue": "95", "ciLowerLimit": "-0.031", "ciUpperLimit": "0.188", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0848", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.097", "ciPctValue": "95", "ciLowerLimit": "-0.013", "ciUpperLimit": "0.207", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0838", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.097", "ciPctValue": "95", "ciLowerLimit": "-0.013", "ciUpperLimit": "0.207", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0014", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.180", "ciPctValue": "95", "ciLowerLimit": "0.070", "ciUpperLimit": "0.289", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.056", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FVC (0-3h) Response After 1 Week", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 1 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.182", "spread": "0.044"}, {"groupId": "OG001", "value": "0.281", "spread": "0.041"}, {"groupId": "OG002", "value": "0.301", "spread": "0.042"}, {"groupId": "OG003", "value": "0.259", "spread": "0.042"}, {"groupId": "OG004", "value": "0.367", "spread": "0.041"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0959", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.099", "ciPctValue": "95", "ciLowerLimit": "-0.018", "ciUpperLimit": "0.216", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0470", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.119", "ciPctValue": "95", "ciLowerLimit": "0.002", "ciUpperLimit": "0.237", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.060", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1960", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.077", "ciPctValue": "95", "ciLowerLimit": "-0.040", "ciUpperLimit": "0.195", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.060", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0020", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.185", "ciPctValue": "95", "ciLowerLimit": "0.068", "ciUpperLimit": "0.302", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FVC (0-3h) Response After 2 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.184", "spread": "0.047"}, {"groupId": "OG001", "value": "0.327", "spread": "0.045"}, {"groupId": "OG002", "value": "0.290", "spread": "0.045"}, {"groupId": "OG003", "value": "0.234", "spread": "0.045"}, {"groupId": "OG004", "value": "0.361", "spread": "0.045"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0270", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.143", "ciPctValue": "95", "ciLowerLimit": "0.016", "ciUpperLimit": "0.269", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.064", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1031", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.106", "ciPctValue": "95", "ciLowerLimit": "-0.021", "ciUpperLimit": "0.233", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.065", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4378", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.050", "ciPctValue": "95", "ciLowerLimit": "-0.077", "ciUpperLimit": "0.177", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.064", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0064", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.176", "ciPctValue": "95", "ciLowerLimit": "0.050", "ciUpperLimit": "0.303", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.064", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Peak FVC (0-3h) Response After 4 Weeks", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Peak FVC (0-3h) values were obtained within 0 - 3 hours after treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to 30 min, 1 h, 2 h, and 3 h relative to dose after 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.199", "spread": "0.051"}, {"groupId": "OG001", "value": "0.274", "spread": "0.048"}, {"groupId": "OG002", "value": "0.267", "spread": "0.048"}, {"groupId": "OG003", "value": "0.235", "spread": "0.048"}, {"groupId": "OG004", "value": "0.439", "spread": "0.048"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2781", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.075", "ciPctValue": "95", "ciLowerLimit": "-0.061", "ciUpperLimit": "0.210", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.069", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3284", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.068", "ciPctValue": "95", "ciLowerLimit": "-0.068", "ciUpperLimit": "0.204", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.069", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6020", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.036", "ciPctValue": "95", "ciLowerLimit": "-0.100", "ciUpperLimit": "0.171", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.069", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.240", "ciPctValue": "95", "ciLowerLimit": "0.104", "ciUpperLimit": "0.375", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.069", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 6-12 h (AUC 6-12h) Response at Week 4", "description": "Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. FEV1 AUC 6-12h was calculated from 6-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "1 hour (h) prior to dose on first day of randomized treatment (baseline) and 1h, 3h, 6h, 9h, 12h relative to dose at Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "56"}, {"groupId": "OG004", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.054", "spread": "0.051"}, {"groupId": "OG001", "value": "0.107", "spread": "0.048"}, {"groupId": "OG002", "value": "0.098", "spread": "0.049"}, {"groupId": "OG003", "value": "0.092", "spread": "0.049"}, {"groupId": "OG004", "value": "0.216", "spread": "0.049"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4331", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.052", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.079", "ciUpperLimit": "0.184", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.067", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5150", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.044", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.089", "ciUpperLimit": "0.178", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.068", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5714", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.038", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.095", "ciUpperLimit": "0.171", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.068", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0177", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "0.162", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.028", "ciUpperLimit": "0.296", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.068", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Mean Evening PEFR After 4 Weeks", "description": "Response was defined as change from baseline. Baseline PEFR was defined as the mean of the evening PEFR measurements obtained during the week just prior to first dose of randomized treatment.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter/minute", "timeFrame": "Baseline and 4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "384.08", "spread": "5.585"}, {"groupId": "OG001", "value": "407.05", "spread": "5.256"}, {"groupId": "OG002", "value": "408.68", "spread": "5.297"}, {"groupId": "OG003", "value": "420.88", "spread": "5.341"}, {"groupId": "OG004", "value": "426.58", "spread": "5.258"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0030", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "22.970", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.883", "ciUpperLimit": "38.057", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.665", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0016", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "24.600", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.446", "ciUpperLimit": "39.754", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.700", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "36.806", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "21.598", "ciUpperLimit": "52.015", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.727", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<.0001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "42.505", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "27.399", "ciUpperLimit": "57.611", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.675", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "PEFR Variability After 4 Weeks", "description": "PEFR variability represents the absolute difference between the highest morning PEFR value and the highest evening PEFR value of 1 day, divided by the arithmetic mean of these 2 PEFR values and expressed as a percent, weekly means.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of PEFR", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.694", "spread": "0.780"}, {"groupId": "OG001", "value": "10.575", "spread": "0.736"}, {"groupId": "OG002", "value": "9.343", "spread": "0.739"}, {"groupId": "OG003", "value": "8.649", "spread": "0.747"}, {"groupId": "OG004", "value": "8.756", "spread": "0.733"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2898", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.118", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.194", "ciUpperLimit": "0.957", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.055", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0270", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.351", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.432", "ciUpperLimit": "-0.269", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.057", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0045", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.045", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.138", "ciUpperLimit": "-0.952", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.063", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0056", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Mixed effect model with terms baseline, treatment, test day, baseline-by-test-day, treatment-by-test-day, and center as random effect", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.937", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.010", "ciUpperLimit": "-0.865", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.053", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Weekly Mean Number of Occasions of Rescue Therapy After 4 Weeks", "description": "Weekly mean number of occasions of rescue therapy used per day (prn salbutamol \\[albuterol\\]) as assessed by the e-Diary (e-Diary incorporated in AM2+).", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Number of Puffs", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.449", "spread": "0.190"}, {"groupId": "OG001", "value": "1.162", "spread": "0.179"}, {"groupId": "OG002", "value": "0.923", "spread": "0.181"}, {"groupId": "OG003", "value": "1.117", "spread": "0.182"}, {"groupId": "OG004", "value": "0.856", "spread": "0.179"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2645", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.287", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.793", "ciUpperLimit": "0.218", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.257", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0423", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.526", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.034", "ciUpperLimit": "-0.018", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.258", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2008", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.332", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.842", "ciUpperLimit": "0.178", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.259", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0218", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.593", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.098", "ciUpperLimit": "-0.087", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.257", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 3 Hours (AUC0-3)", "description": "AUC0-3 represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "28"}, {"groupId": "OG004", "value": "44"}]}], "classes": [{"title": "Olodaterol (N=0;0;0;20;44)", "categories": [{"measurements": [{"groupId": "OG003", "value": "11.8", "spread": "35.2"}, {"groupId": "OG004", "value": "17.8", "spread": "42.1"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;0;28;36)", "categories": [{"measurements": [{"groupId": "OG003", "value": "9.14", "spread": "48.6"}, {"groupId": "OG004", "value": "20.3", "spread": "48.0"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Concentration (Cmax)", "description": "Cmax represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram/milliliter", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "38"}, {"groupId": "OG003", "value": "54"}, {"groupId": "OG004", "value": "58"}]}], "classes": [{"title": "Olodaterol (N=0;0;21;44;58)", "categories": [{"measurements": [{"groupId": "OG002", "value": "3.54", "spread": "48.4"}, {"groupId": "OG003", "value": "4.63", "spread": "59.7"}, {"groupId": "OG004", "value": "8.24", "spread": "68.6"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;38;54;57)", "categories": [{"measurements": [{"groupId": "OG002", "value": "3.57", "spread": "82.1"}, {"groupId": "OG003", "value": "5.00", "spread": "50.4"}, {"groupId": "OG004", "value": "9.54", "spread": "69.7"}]}]}]}, {"type": "SECONDARY", "title": "Time From Dosing to the Maximum Concentration (Tmax)", "description": "tmax represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma.", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h) and 3h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "38"}, {"groupId": "OG003", "value": "54"}, {"groupId": "OG004", "value": "58"}]}], "classes": [{"title": "Olodaterol (N=0;0;21;44;58)", "categories": [{"measurements": [{"groupId": "OG002", "value": "0.183", "lowerLimit": "0.0830", "upperLimit": "2.97"}, {"groupId": "OG003", "value": "0.234", "lowerLimit": "0.0830", "upperLimit": "2.83"}, {"groupId": "OG004", "value": "0.267", "lowerLimit": "0.0670", "upperLimit": "1.07"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;38;54;57)", "categories": [{"measurements": [{"groupId": "OG002", "value": "2.97", "lowerLimit": "0.117", "upperLimit": "3.05"}, {"groupId": "OG003", "value": "2.97", "lowerLimit": "0.233", "upperLimit": "3.20"}, {"groupId": "OG004", "value": "2.97", "lowerLimit": "0.100", "upperLimit": "3.22"}]}]}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 3 Hours at Steady State (AUC0-3,ss)", "description": "AUC0-3,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=3 at steady state.", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "38"}, {"groupId": "OG003", "value": "44"}, {"groupId": "OG004", "value": "54"}]}], "classes": [{"title": "Olodaterol (N=0;0;0;38;53)", "categories": [{"measurements": [{"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}, {"groupId": "OG003", "value": "13.0", "spread": "42.7"}, {"groupId": "OG004", "value": "25.5", "spread": "56.5"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;38;44;54)", "categories": [{"measurements": [{"groupId": "OG002", "value": "7.71", "spread": "62.2"}, {"groupId": "OG003", "value": "9.04", "spread": "64.2"}, {"groupId": "OG004", "value": "19.0", "spread": "59.4"}]}]}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss)", "description": "AUC0-6,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=6 at steady state.", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "32"}, {"groupId": "OG004", "value": "50"}]}], "classes": [{"title": "Olodaterol (N=0;0;0;32;50)", "categories": [{"measurements": [{"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}, {"groupId": "OG003", "value": "25.3", "spread": "35.7"}, {"groupId": "OG004", "value": "46.3", "spread": "50.3"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;21;23;33)", "categories": [{"measurements": [{"groupId": "OG002", "value": "19.2", "spread": "58.2"}, {"groupId": "OG003", "value": "21.3", "spread": "56.4"}, {"groupId": "OG004", "value": "37.6", "spread": "54.2"}]}]}]}, {"type": "SECONDARY", "title": "Area Under Curve From 0 to 24 Hours at Steady State (AUC0-24,ss)", "description": "AUC0-24,ss represents the area under the concentration curve of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma from 0 to time t=24 at steady state.", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram*hours/milliliter", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "20"}, {"groupId": "OG004", "value": "44"}]}], "classes": [{"title": "Olodaterol", "categories": [{"measurements": [{"groupId": "OG003", "value": "83.7", "spread": "30.3"}, {"groupId": "OG004", "value": "147", "spread": "49.5"}]}]}, {"title": "Olodaterol glucuronide", "categories": [{"measurements": [{"groupId": "OG003", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}, {"groupId": "OG004", "value": "NA", "spread": "NA", "comment": "No patients analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Maximum Concentration at Steady State (Cmax,ss)", "description": "Cmax,ss represents the maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Picogram/milliliter", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "46"}, {"groupId": "OG003", "value": "46"}, {"groupId": "OG004", "value": "56"}]}], "classes": [{"title": "Olodaterol N=(0;0;39;45;56)", "categories": [{"measurements": [{"groupId": "OG002", "value": "3.19", "spread": "35.0"}, {"groupId": "OG003", "value": "5.09", "spread": "53.0"}, {"groupId": "OG004", "value": "12.1", "spread": "69.2"}]}]}, {"title": "Olodaterol glucuronide N=(0;0;46;46;54)", "categories": [{"measurements": [{"groupId": "OG002", "value": "4.16", "spread": "46.8"}, {"groupId": "OG003", "value": "5.04", "spread": "57.4"}, {"groupId": "OG004", "value": "9.19", "spread": "53.6"}]}]}]}, {"type": "SECONDARY", "title": "Time From Dosing to the Maximum Concentration at Steady State (Tmax,ss)", "description": "tmax,ss represents the time from dosing to maximum concentration of olodaterol and olodaterol glucuronide (a metabolite of olodaterol) in plasma at steady state.", "populationDescription": "All evaluable patients were included in the pharmacokinetic (PK) analysis. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK parameters or had insufficient data.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "30 minutes (mins) before drug administration and 5mins, 10mins, 20mins, 40mins, 1 hour (h), 3h and 6h after drug administration", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "46"}, {"groupId": "OG003", "value": "46"}, {"groupId": "OG004", "value": "56"}]}], "classes": [{"title": "Olodaterol (N=0;0;39;45;56)", "categories": [{"measurements": [{"groupId": "OG002", "value": "0.333", "lowerLimit": "0.0830", "upperLimit": "2.92"}, {"groupId": "OG003", "value": "0.333", "lowerLimit": "0.0830", "upperLimit": "2.93"}, {"groupId": "OG004", "value": "0.333", "lowerLimit": "0.0830", "upperLimit": "1.08"}]}]}, {"title": "Olodaterol glucuronide (N=0;0;46;46;54)", "categories": [{"measurements": [{"groupId": "OG002", "value": "3.00", "lowerLimit": "0.100", "upperLimit": "6.00"}, {"groupId": "OG003", "value": "3.00", "lowerLimit": "0.917", "upperLimit": "6.02"}, {"groupId": "OG004", "value": "2.97", "lowerLimit": "0.350", "upperLimit": "6.05"}]}]}]}, {"type": "SECONDARY", "title": "Total Score in Asthma Control Questionnaire After 4 Weeks", "description": "Adequacy of asthma control was assessed using a scale of: 0=totally controlled, to 6=Severely uncontrolled.", "populationDescription": "Full analysis set (FAS) is defined as all randomized patients who received at least one dose of treatment and had baseline data for at least one endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "58"}, {"groupId": "OG003", "value": "59"}, {"groupId": "OG004", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.456", "spread": "0.089"}, {"groupId": "OG001", "value": "1.314", "spread": "0.086"}, {"groupId": "OG002", "value": "1.260", "spread": "0.086"}, {"groupId": "OG003", "value": "1.129", "spread": "0.084"}, {"groupId": "OG004", "value": "1.181", "spread": "0.084"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2156", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.142", "ciPctValue": "95", "ciLowerLimit": "-0.368", "ciUpperLimit": "0.083", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.114", "estimateComment": "Olo 2 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0869", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.197", "ciPctValue": "95", "ciLowerLimit": "-0.422", "ciUpperLimit": "0.029", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.114", "estimateComment": "Olo 5 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0044", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.328", "ciPctValue": "95", "ciLowerLimit": "-0.552", "ciUpperLimit": "-0.103", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.114", "estimateComment": "Olo 10 mcg qd minus Placebo"}, {"groupIds": ["OG000", "OG004"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0158", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance model with terms for baseline, treatment, centre (centre random, all other effects fixed)", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.276", "ciPctValue": "95", "ciLowerLimit": "-0.499", "ciUpperLimit": "-0.052", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.113", "estimateComment": "Olo 20 mcg qd minus Placebo"}]}, {"type": "SECONDARY", "title": "Clinical Relevant Abnormalities for Vital Signs, ECG and Physical Examination", "description": "Clinical relevant abnormalities for vital signs, ECG and physical examination. Any new or clinically relevant worsening of baseline conditions was reported as adverse events.", "populationDescription": "Treated set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "60"}, {"groupId": "OG003", "value": "60"}, {"groupId": "OG004", "value": "61"}]}], "classes": [{"title": "Palpitations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "2"}]}]}, {"title": "Ventricular extrasystoles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Blood creatine phosphokinase increased", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Testing: Average Change From Baseline of Potassium", "description": "Laboratory testing: Average change from baseline of potassium measured on test-days. Pre-dose value on test day 1 is the baseline value.", "populationDescription": "Treated Set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline and 29 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler."}, {"id": "OG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler."}, {"id": "OG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "52"}, {"groupId": "OG003", "value": "56"}, {"groupId": "OG004", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.98", "spread": "NA", "lowerLimit": "0.94", "upperLimit": "1.02"}, {"groupId": "OG001", "value": "0.97", "spread": "NA", "lowerLimit": "0.93", "upperLimit": "1.02"}, {"groupId": "OG002", "value": "1.00", "spread": "NA", "lowerLimit": "0.95", "upperLimit": "1.05"}, {"groupId": "OG003", "value": "0.99", "spread": "NA", "lowerLimit": "0.96", "upperLimit": "1.03"}, {"groupId": "OG004", "value": "0.97", "spread": "NA", "lowerLimit": "0.92", "upperLimit": "1.02"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "4 weeks", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Matching Placebo delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 54, "otherNumAffected": 9, "otherNumAtRisk": 54}, {"id": "EG001", "title": "Olo 2 mcg qd", "description": "Olodaterol 2 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 61, "otherNumAffected": 9, "otherNumAtRisk": 61}, {"id": "EG002", "title": "Olo 5 mcg qd", "description": "Olodaterol 5 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 11, "otherNumAtRisk": 60}, {"id": "EG003", "title": "Olo 10 mcg qd", "description": "Olodaterol 10 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 1, "seriousNumAtRisk": 60, "otherNumAffected": 7, "otherNumAtRisk": 60}, {"id": "EG004", "title": "Olo 20 mcg qd", "description": "Olodaterol 20 mcg qd (morning) delivered by the Respimat Inhaler.", "seriousNumAffected": 1, "seriousNumAtRisk": 61, "otherNumAffected": 11, "otherNumAtRisk": 61}], "seriousEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 61}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 61}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 61}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 61}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 61}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 61}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 61}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 61}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 60}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 61}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication"}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim Pharmaceuticals", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000549647", "term": "Olodaterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M254406", "name": "Olodaterol", "asFound": "Kinesiotape", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}